Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Preimplantation genetic testing for BReast CAncer gene 1 and risk-reducing surgery is more effective at age 35 than age 40.

Fertility and sterility - 1 Jun 2026

Hunkler Kiley, Boedeker David, Bulles Kelby, Combs Joshua, Brown Jill

Abstract excerpt

OBJECTIVE: To compare the cost-effectiveness of in vitro fertilization (IVF) with preimplantation genetic testing for monogenic disorders (PGT-M) at age 35, followed by risk-reducing bilateral salpingo-oophorectomy, to delaying interventions to age 40 among BRCA1 (BReast CAncer gene 1) mutation carriers. DESIGN: A cost-effectiveness analysis using a Markov mathematical model. SUBJECTS: Probabilities, cost data,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cost-Benefit Analysis
Share to Fertilization in Vitro

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genes, BRCA1

Share to Markov Chains

Share to Models, Economic

Share to Preimplantation Diagnosis

Share to Quality-Adjusted Life Years

Share to Salpingo-oophorectomy

Source

Identifiers

PMID: 41724460
DOI: 10.1016/j.fertnstert.2026.02.025

Genes

BRCA1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Preimplantation genetic testing for BReast CAncer gene 1 and risk-reducing surgery is more effective at age 35 than age 40.PMID 41724460Read ↗

Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation.Semantic proximity Read ↗

Cost effectiveness of in vitro fertilisation and preimplantation genetic testing to prevent transmission of BRCA1/2 mutations.Semantic proximity Read ↗

Decision-analytic evaluation of the comparative effectiveness and cost-effectiveness of strategies to prevent breast and ovarian cancer in German women with BRCA-1/2 mutations.Semantic proximity Read ↗

Decision analysis of prophylactic surgery or screening for BRCA1 mutation carriers: a more prominent role for oophorectomy.Semantic proximity Read ↗

Cost-effectiveness of different strategies to prevent breast and ovarian cancer in German women with a BRCA 1 or 2 mutation.Semantic proximity Read ↗

A MDP model for breast and ovarian cancer intervention strategies for BRCA1/2 mutation carriers.Semantic proximity Read ↗

Testing for the BRCA1 and BRCA2 breast-ovarian cancer susceptibility genes: a decision analysis.Semantic proximity Read ↗

Cost-Effectiveness of Population-Based Multigene Testing for Breast and Ovarian Cancer PreventionSemantic proximity Read ↗

A SART data cost-effectiveness analysis of planned oocyte cryopreservation versus in vitro fertilization with preimplantation genetic testing for aneuploidy considering ideal family sizeSemantic proximity Read ↗

Preimplantation genetic testing for BRCA gene mutation carriers: a cost effectiveness analysis.Semantic proximity Read ↗

Cost-effectiveness of preimplantation genetic screening for women older than 37 undergoing in vitro fertilizationSemantic proximity Read ↗

Salpingectomy With Delayed Oophorectomy in BRCA1/2 Mutation Carriers: Estimating Ovarian Cancer Risk.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.